Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines - PubMed (original) (raw)
Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines
Shin Ling Hwang et al. Cell Res. 2005 Mar.
Abstract
Indoleamine 2, 3-dioxygenase (IDO) is a rate-limiting enzyme for the tryptophan catabolism. In human and murine cells, IDO inhibits antigen-specific T cell proliferation in vitro and suppresses T cell responses to fetal alloantigens during murine pregnancy. In mice, IDO expression is an inducible feature of specific subsets of dendritic cells (DCs), and is important for T cell regulatory properties. However, the effect of IDO and tryptophan deprivation on DC functions remains unknown. We report here that when tryptophan utilization was prevented by a pharmacological inhibitor of IDO, 1-methyl tryptophan (1MT), DC activation induced by pathogenic stimulus lipopolysaccharide (LPS) or inflammatory cytokine TNF-alpha was inhibited both phenotypically and functionally. Such an effect was less remarkable when DC was stimulated by a physiological stimulus, CD40 ligand. Tryptophan deprivation during DC activation also regulated the expression of CCR5 and CXCR4, as well as DC responsiveness to chemokines. These results suggest that tryptophan usage in the microenvironment is essential for DC maturation, and may also play a role in the regulation of DC migratory behaviors.
Similar articles
- Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.
Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH. Mellor AL, et al. Int Immunol. 2004 Oct;16(10):1391-401. doi: 10.1093/intimm/dxh140. Epub 2004 Sep 6. Int Immunol. 2004. PMID: 15351783 - IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells.
Hill M, Tanguy-Royer S, Royer P, Chauveau C, Asghar K, Tesson L, Lavainne F, Rémy S, Brion R, Hubert FX, Heslan M, Rimbert M, Berthelot L, Moffett JR, Josien R, Grégoire M, Anegon I. Hill M, et al. Eur J Immunol. 2007 Nov;37(11):3054-62. doi: 10.1002/eji.200636704. Eur J Immunol. 2007. PMID: 17948274 - Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-indoleamine 2,3-dioxygenase axis.
Xiao BG, Liu X, Link H. Xiao BG, et al. Steroids. 2004 Sep;69(10):653-9. doi: 10.1016/j.steroids.2004.05.019. Steroids. 2004. PMID: 15465110 - Indoleamine 2,3-dioxygenase in transplantation.
Mulley WR, Nikolic-Paterson DJ. Mulley WR, et al. Nephrology (Carlton). 2008 Jun;13(3):204-11. doi: 10.1111/j.1440-1797.2007.00921.x. Epub 2008 Jan 23. Nephrology (Carlton). 2008. PMID: 18221253 Review. - Indoleamine 2,3-dioxygenase: from catalyst to signaling function.
Fallarino F, Grohmann U, Puccetti P. Fallarino F, et al. Eur J Immunol. 2012 Aug;42(8):1932-7. doi: 10.1002/eji.201242572. Eur J Immunol. 2012. PMID: 22865044 Review.
Cited by
- Age-related increase of kynurenine enhances miR29b-1-5p to decrease both CXCL12 signaling and the epigenetic enzyme Hdac3 in bone marrow stromal cells.
Elmansi AM, Hussein KA, Herrero SM, Periyasamy-Thandavan S, Aguilar-Pérez A, Kondrikova G, Kondrikov D, Eisa NH, Pierce JL, Kaiser H, Ding KH, Walker AL, Jiang X, Bollag WB, Elsalanty M, Zhong Q, Shi XM, Su Y, Johnson M, Hunter M, Reitman C, Volkman BF, Hamrick MW, Isales CM, Fulzele S, McGee-Lawrence ME, Hill WD. Elmansi AM, et al. Bone Rep. 2020 Apr 23;12:100270. doi: 10.1016/j.bonr.2020.100270. eCollection 2020 Jun. Bone Rep. 2020. PMID: 32395570 Free PMC article. - Unveiling the growing significance of metabolism in modulating immune cell function: exploring mechanisms and implications; a review.
Aderinto N, Abdulbasit MO, Tangmi ADE, Okesanya JO, Mubarak JM. Aderinto N, et al. Ann Med Surg (Lond). 2023 Sep 13;85(11):5511-5522. doi: 10.1097/MS9.0000000000001308. eCollection 2023 Nov. Ann Med Surg (Lond). 2023. PMID: 37915697 Free PMC article. - Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, Berglund JP, Tsai M, Maecker H, O'Riordan G, Galli SJ, Nadeau KC. Syed A, et al. J Allergy Clin Immunol. 2014 Feb;133(2):500-10. doi: 10.1016/j.jaci.2013.12.1037. J Allergy Clin Immunol. 2014. PMID: 24636474 Free PMC article. Clinical Trial. - A phase I study of indoximod in patients with advanced malignancies.
Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. Soliman HH, et al. Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216. Oncotarget. 2016. PMID: 27008709 Free PMC article. Clinical Trial. - Chromatographic analysis of tryptophan metabolites.
Sadok I, Gamian A, Staniszewska MM. Sadok I, et al. J Sep Sci. 2017 Aug;40(15):3020-3045. doi: 10.1002/jssc.201700184. Epub 2017 Jun 26. J Sep Sci. 2017. PMID: 28590049 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials